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INTRODUCTION 
ONE FACTOR which supposedly limits the effectiveness of 
chemotherapy in cancer treatment is a reduced net uptake of 
cytostatic drug into the tumour cells, caused by the over- 
expression of plasma membrane drug transporters, leading to 
a multidrug resistant (MDR) phenotype. It has now been 
shown that two drug transporter proteins affect the net uptake 
of lipophilic natural product agents by human cancer cells. 
These proteins are P-glycoprotein (Pgp) and multidrug resist- 
ance-associated protein (MRP). With the availability of gene 
probes and monoclonal antibodies against these proteins, the 
incidence of Pgp and MRP in clinical tumour specimens has 
been determined [l-4]. In general, results from many of the 
published studies on Pgp distribution in tissues and tumours 
are qualitatively quite similar, showing prominent Pgp 
expression in certain tissues (adrenal gland, liver, epithelium 
of gastrointestinal tract) and tumours (differentiated renal and 
colon cancers), but low, heterogeneous or undetectable Pgp 
in other tissues and tumours [l-3]. As far as MRP expression 
is concerned, the available probes and antibodies have been 
used to study its general distribution pattern [4-S]. 
However, what the quantitative role of Pgp (and MRP) is in 
clinical drug resistance is unknown, with current methodology 
giving irreproducible and inadequate answers [9-l 11. Possible 
reasons for this and possible improvements in MDR detection 
methodology are the topic of this paper. 
GENERAL CONSIDERATIONS ON I’gp AND MRI’ 
DETECTION 
The primary point to consider is the sensitivity of the 
methodology to be used. It has now been established in a 
number of investigations that Pgp levels in clinical material 
are low, especially in those cancer types which are responsive 
to chemotherapy and in which expression of resistance mark- 
ers may have some impact on clinical decisions. Cancers with 
relatively high Pgp expression, such as adrenocortical cancer 
and differentiated renal cell or colon cancers, are intrinsically 
resistant to all MDR drugs and, therefore, analysis of such 
markers is not expected to be helpful in the clinic [12]. In 
contrast, in diseases such as leukaemia, myeloma, lymphomas 
and solid tumours, such as breast cancer and ovarian cancer, 
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knowledge of Pgp, MRP or other resistance markers, such as 
lung resistance protein/major vault protein (LRPIMVP) (see 
Izquierdo and colleagues, pages 9799984), glutathione status 
or topoisomerase II activity, may be helpful in certain patients. 
For instance, one relatively recent issue is the role of 
MDRliPgp in ovarian cancer, now that treatment with paclit- 
axe1 is being increasingly used for the treatment of this disease 
[ 131. Since paclitaxel is very efficiently transported by Pgp, it 
could be that low levels of Pgp expression, such as those 
occurring in ovarian cancer, might be of critical importance. 
If it is true that even very low levels of Pgp expression are 
predictive for chemotherapy outcome, as suggested for ovarian 
cancer and small cell lung cancer (samples were considered 
positive with a value of MDRl mRNA expression between 
KB3-1 “sensitive” and less than 2-fold resistance KB8 cells), 
then probably only polymerase chain reaction (PCR) tech- 
niques are suitable for such studies [ 141. For MRP, such 
studies have not yet been performed, but it seems clear that 
MRP is constitutively expressed at a low level in almost every 
cell, with relatively high expression in only a few tissues, such 
as bronchi, heart, muscle and adrenal cortex [7], and tumours 
(lymphocytic leukaemia, oesophagus squamous cell carci- 
noma, non-small cell lung carcinoma) [4, 71. This implies that 
methods of detecting MRP must not only be sensitive (i.e. 
detect low levels of MRP expression), but must also be able to 
quantitate low levels of expression. 
In this paper, we will discuss some methodological consider- 
ations of importance for reliable Pgp and MRP detection in 
clinical tumour samples. Our main focus will be on sensitivity 
and quantitation, since it is likely that we shall have to aim at 
detection and discrimination of low levels of expression which 
differ by a factor of two or less. While a routinely applicable 
method needs to be specific and quantitative, it should be 
noted that, to our knowledge, no published MDR detection 
methods have yet been tested rigorously for their accuracy and 
reproducibility (day-to-day variation of real samples, etc.), as 
is required for validating analytical chemical procedures. In 
fact, the failure to do so before including a test in a clinical 
study might very well be the cause of much confusion and, 
more disturbingly, of the possibility that wrong conclusions 
are drawn from such studies. 
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mRNA MEASUREMENTS 
Determination ofMDRl mRNA expression in many human 
tumour samples requires a method with the sensitivity of the 
reverse transcriptase PCR (RT-PCR) [3]. Another method 
with a high sensitivity, provided that sufficient material is 
available, is the RNase protection assay [15]. It has been 
estimated that with an RNase protection assay, approximately 
1 x 106 target transcripts can be detected, in contrast to 
approximately 1 x 10’ with Northern blotting [ 161. 
RT-ER 
Measurement of MDRl or MRP mRNA (over)expression 
in clinical tumour samples requires appropriate controls for 
recovery of RNA and quantitation of the signals obtained. 
The choice of probes and enzyme concentrations (RNase 
protection), primers and reaction conditions (RT-PCR) and a 
detection system may be critical and may be different per 
tumour type (e.g. choice of control gene y-actin, p-actin, &- 
microglobulin or glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH); recent practical laboratory guides will give the 
reader information on all the general theoretical and practical 
considerations). However, it should be borne in mind that, 
because RT-PCR is a very sensitive, quantitative method for 
determining gene expression it requires highly standardised 
reaction conditions for each sample and control. This makes 
the method quite laborious, since serial dilution of cDNAs 
to ensure that amplification is in the exponential range, is 
crucial [ 16,171. 
As an example of the importance of quality control of the 
methodology, the results of three studies which measured 
MDRl mRNA expression in human blood cell lineages have 
been compared [ 18-201. In general, all three papers agree that 
the highest Pgp expression is detected in CD56+ natural 
killer (NK) cells and CD8+ T suppressor cells, that Pgp is 
intermediate in CD4+ T helper cells and absent in CD14+ 
monocytes, based on Pgp surface expression or dye efflux. 
Two of the papers used the 8226dox6 myeloma cell line as a 
control. In one study, which used an RT-PCR method with 
an in vitro synthesised RNA standard, the highest MDRl- 
expressing (CD56”) cells had a value of 50% that of 8226dox6 
[ZO]. The other study, which used an RT-PCR method with 
P,-microglobulin primers as a control, found an MDRl 
mRNA expression in CD8+ and CD56’ cells of more than 6- 
fold that of 8226dox6 and 2-fold that of 8226dox40, a myel- 
oma cell line which was more than lOO-fold resistant to 
doxorubicin (Dox) [ 191. Such a high expression of Pgp in 
unselected cells is highly unlikely and, if real, would have 
enormous implications for chemotherapy. More likely, these 
results cannot be regarded as quantitative and cannot be 
compared with other studies. Again, it is important to realise 
that this has to be seen in the context of detecting a factor 
of 1.5 or 2 difference in Pgp/MDRl expression at a level 
considerably lower than the 32-fold doxorubicin-resistant 
8226dox6 cells [20]. 
RNase protection 
We have used RNase protection in the past to show that the 
low MDRl mRNA expression in parental SW-1573 lung 
cancer cells is actually downregulated upon induction of the 
non-Pgp MDR phenotype in this cell line. The expression 
becomes undetectable by RNase protection or by RT-PCR 
in SW-1573/2R50 and 2R120 non-Pgp MDR cells [21]. 
Subsequently, we have studied MDRl and MRP mRNA 
expression in acute myeloid leukaemias (AML) with an RNase 
protection assay, quantitated by densitometric scanning of the 
labelled bands, corresponding to MDRl or MRP mRNA, and 
divided by the y-actin band, used to control for RNA loading. 
We did not find a correlation between the values found for 
Pgp expression measured by flow cytometric labelling of viable 
cells with monoclonal antibody MRK-16 (see below) and 
MDRl mRNA in these samples (Figure 1) [22]. Although the 
discussion about the appropriate control (-y-actin, p-actin, &- 
microglobulin or GAPDH) is partly the same as for RT- 
PCR, there is at least one plausible biological reason for this 
discrepancy. MDRl mRNA expression levels may vary 200- 
fold between different acute myeloid leukaemias (AMLs) with 
some AMLs having very low expression (Figure 1). This 
means that a low percentange of contaminating normal 
MDR1-expressing cells (e.g. T cells) may have a significant 
increasing effect on low MDRl-expressing AMLs. Contami- 
nating normal lymphocytes may also lower the MDRl mRNA 
signal of high expressers. In both cases, these problems may 
be less when using a flow cytometric Pgp assay, because a low 
percentage (e.g. 1%) of relatively high Pgp expressers will be 
separate from the main peak. Alternatively, to a certain extent 
normal cells can be gated out by scatter characteristics. 
Another reason to be more confident of a flow cytometric 
Pgp protein assay is that we have seen examples of MDRl 
mRNA-expressing cell lines, without detectable Pgp 
expression or function (see SW-1573 cell line in Figure 1). 
As far as MRP expression is concerned, the above consider- 
ations might be less relevant since all normal peripheral blood 
cells, regardless of cell lineage, express a similar basal level 
of MRP mRNA [23] and, accordingly, the variation in its 
expression in AMLs seems to be less (about a factor 10) 
than for MDRl mRNA expression [22]. This allows less 
interference with the resulting tumour signal by small subpop- 
ulations of contaminating normal cells. Of course, the loss of 
any insight into the heterogeneity of expression within the 
tumour cell population, when assayed by RT-PCR of mRNA 
from a cell homogenate, remains a drawback of this technique 
for MRP, as well as for MDRl mRNA. 
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Figure 1. Correlation between MDRl mRNA and P-glyco- 
protein (Pgp) expression in acute myeloid leukaemia (AML) 
and cell lines. MDRl mRNA was measured with RNase protec- 
tion assay. Pgp was measured with MRK16 (5 ~glml, 60 min, 
room temperature) and FITC-labelled second antibody and 
quantified on a FACSTAR (details in [22]). 
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In situ hybridisation Imnwzohistolcytochenzistry 
A resolution of cellular heterogeneity at the mRNA level 
can be achieved by in situ hybridisation. It has been shown 
by this technique that, in lung cancers, MRP expression 
is particularly strong in lymphocyte infiltrate and in tissue- 
invading tumour cells [24]. Thus, while useful in certain cases, 
in situ hybridisation has not gained a place among current 
MDR screening protocols. The reasons for this might be that 
it is a rather laborious technique, for which the sensitivity in 
comparison to other methods with cellular resolution (i.e. 
immunohistochemistry) has not yet been documented in clini- 
cal samples. One study has compared MDRl in situ hybridis- 
ation with immunocytochemistry, immunoblotting, flow cyto- 
metry and RT-PCR in resistant cell lines (lowest resistance 
factor of approximately 20-30 for vincristine), and it appeared 
that quantification of the lower signals against the background 
was not satisfactory [25]. Reasonably satisfactory results were 
reported in 36 “freshly established cell lines” from childhood 
acute lymphoblastic leukaemia samples (80% concordance 
between RT-PCR and in situ hybridisation). However, discor- 
dant results have been reported with MRK16 staining [26]. 
The single most widely adopted technique for Pgp detection 
in clinical tumour specimens is immunohistochemical stain- 
ing. To date, two laboratories have published immunocytoch- 
emical data, suggesting that (extremely) low Pgp levels can be 
detected by immunohistoicytochemical staining. A study by 
Grogan and coworkers [30] suggests that immunocytochemis- 
try, when performed under stringently controlled conditions, 
can be a reliable test for Pgp expression in myeloma and 
may come “within the realm of everyday hospital laboratory 
expertise”. However, it must be noted that the lowest resistant 
cell line used in this study to define the limit of detection was 
the 82261dox4 myeloma cell line. This cell line has an MDR 
phenotype which is still high compared to clinical samples. 
We showed that 8226idox4 cells had a relatively low 
nuclearicytoplasmic doxorubicin ratio (2.2 compared to 3.9 
for 82263 cells; see below), a functional MDR parameter 
[31], and we estimated the number of Pgp molecules per 
8226/dox4 cell to be in the order of 200000 similar to that of 
KB8-5 cells (unpublished data). A lower level of detection is 
still needed for many tumour types. 
PROTEIN DETECTION 
The techniques used for Pgp detection are immunoblotting, 
immunohistoicytochemistry and flow cytometry. From all the 
techniques used for MDRliPgp detection, these methods 
based on monoclonal antibodies are the most widely used. 
The reason for this is undoubtedly their relatively easy appli- 
cation for routine pathological screening. Accordingly, many 
papers have been published over the last 10 years which use 
these immunostaining methods to measure Pgp in archival 
clinical tumour specimens. Prospective studies in which 
tumour samples are prepared according to controlled, 
optimised protocols for fixation, antigen preservation or 
retrieval, reaction conditions etc., are still very scare. 
Western inmu?zoblotti?~g 
Western blotting is not a method of first choice, because 
evidently no distinction can be made between tumour or 
stromal cells which is an important issue in MDR analyses. 
In addition, the relatively laborious methodology does not 
facilitate routine application. Nevertheless, since by Western 
blot analysis, a positive identification of the molecular weight 
of Pgp or MRP can be obtained, which may help in the 
elucidation of crossreactions in suspected cases, it may help in 
confirming the presence of these proteins. One has to be aware 
of the possibility of falsely negative or positive results which 
may be caused by proteolytic breakdown or cross-reaction of 
the antibodies. The most used monoclonal antibody for Pgp 
is C2 19, which may crossreact with the MDRS-encoded Pgp, 
for instance in B-cell prolymphocytic leukaemia [27]. Less 
crossreaction with MDRSiPgp has been reported for C494 
and JSB-1 antibodies [28]. Similarly, Western immuno- 
blotting may help in identifying proteins crossreactive with 
monoclonal antibodies against MRP, such as MRPrl and 
MRPm6 [29]. With the advent of enhanced chemilumi- 
nescence (ECL) detection, the methodology now seems to be 
sensitive enough to detect KB8 level of Pgp without the need 
for lZ51-based detection [27]. In summary, in selected cases, 
immunoblotting may be applied to confirm the presence of 
Pgp or MRP. 
In order to measure such low levels of Pgp expression in 
paraffin-embedded, formalin-fixed, solid tumour specimens, 
a four-layer immunoperoxidase-based “sandwich” technique 
has been used by Chan and colleagues [32] In a retrospective 
study, it was found that Pgp was highly predictive for prog- 
nosis in childhood rhabdomyosarcoma and neuroblastoma 
[32]. Unfortunately, these authors did not use the same con- 
trol cell lines as other investigators and, therefore, we cannot 
compare the sensitivity of their method with the quantitative 
PCR in KB cell lines [3]. One paper claiming to apply the 
method of Chan and colleagues could not detect the highly 
resistant KB8-5 cells [33]. Another team claims to have 
developed an improved multilayer peroxidase technique [34]. 
They use overnight staining with the primary antibody JSB-1, 
which, they say, performs better than C2 19 in paraffin sections 
because its epitope appears to be more resistant to tissue 
processing [34]. However, KB8-5 cells again seem to be in the 
margin of detection. In the experience of other investigators, 
who use conventional peroxidase-based immunostaining, 
JSB-1 and other antibodies give an unsatisfactory, non-specific 
background in paraffin-embedded material [35]. Therefore, 
as a conclusion from the published immunoperoxidase-based 
studies, Pgp detection above a certain expression level, which 
probably varies per study, is possible [36], but the general 
applicability of a sensitive Pgp detection method has yet to be 
proven. From this, it may be inferred that the expression 
level and accordingly the role of Pgp in many low-level Pgp- 
expressing or initially chemotherapy-sensitive tumour types 
has not yet been adequately studied. There is, for example, no 
published study using a highly sensitive, quality controlled 
immunoperoxidase method examining the expression of Pgp 
in breast cancer. This may even hold for frozen sections which 
seem to be relatively accessible to Pgp staining [37-391. 
An alkaline phosphatase anti-alkaline phosphatase 
(APAAP) version of the four-layer technique has been pub- 
lished, which can be used for staining myeloblasts in which 
endogenous peroxidase is present [40]. With this technique, 
8226idox6 cells are scored as having a 3+ plasma membrane 
staining for Pgp. We have used a double APAAP staining for 
acetone-fixed AML samples (with 15 pgiml JSB-1 or C219 
primary antibody incubation for 1 h at room temperature) and 
could only stain those AMLs with the highest Pgp expression, 
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which are between the expression of KB8 and KB8-5 cells as 
determined with flow cytometry. Unfortunately, KB cells have 
a high background with the APAAP technique and could not 
be used as controls. 
In contrast to immunocytochemical Pgp detection, the 
detection of MRP in tumour cell lines with currently available 
monoclonal antibodies (MRPrl, MRPrn6) [29], using the 
same methodology, is very sensitive. The MRPrl, MRPrn5 
and MRPrn6 antibodies all perform better on fomaldehyde- 
fixed, paraffin-embedded than on frozen sections, probably 
because they recognise non-conformational epitopes [7]. We 
used MRPrl on acetone-fixed cytospins of a series of small 
cell lung cancer cell lines with increasing drug resistance factor 
[41] to test the sensitivity of the double APAAP method for 
MRP detection. These results (see Table 1) showed that 
plasma membrane-associated MRP could be detected in the 
parent GLC, cells in accordance with the finding that a 
baseline MRP mRNA expression is present in all tissues. 
Thus, the major difficulty will be to make a reliable distinction 
between MRJ? staining of GLC4 (“sensitive”) cells and that of 
2-fold resistant cells. Preliminary results of the staining of 
AML samples showed little variation, and possibly an optical 
image analysis system, such as used by Grogan and associates 
DO], would be helpful. In addition, preliminary data have 
suggested that MRP might be in~acellularly located in various 
normal tissues, but located in mainly plasma membranes in 
turnour cell lines and clinical tumour samples [7]. Since, at 
present, the role of intracellular MRP in mediating drug 
transport is unclear, it seems imperative to document unam- 
biguously whether MRP is on the plasma or intracellular 
membranes. 
In conclusion, it is clear that reliable, sensitive detection of 
Pgp with immunohistoicytochemical techniques in clinical 
material requires a commitment and investment in personnel 
Table I. MRP detect-ion in GLC, sublines 
Cell line* 
Dox Flow Flow 
resistance* APAAPt cytometry* cytometrys 
GLC, 
GLC,-ADR, 
GLC,-ADRpr 
GLC,-ADR,,,, 
1 ii- 1.6 2.7-1.8 
2 +i- + 1.9 n.d.-2.6 
11 +i 2.3 4.0-4.7 
150 ++++ 7.4 13.6-21.1 
APAAP, alkaline phosphatase anti-alkaline phosphatase; Dox, 
doxorubicin; n.d., not determined. 
*MN’ mRNA expression and resistance factors in these cell lines are 
described in [4 11. tProcedure “double APAAP” immunocytochemis- 
try: ice-cold acetone fixation (10 min); 20 min pre-incubation with 
blocking buffer (10% rabbit serum + 1% BSA); 60 min primary 
antibody MRPrl (1.7 &ml; room temperature); 30 min rabbit-anti- 
rat (RAR, Dakopatts 150, room temperature); 30 min APAAP (rat; 
Dakopatts I:25, room temperature); repeat RAR and APAAP step; 
30 min alkaline phosphatase substrate (room temperature, dark); 
counterstain: haematoxylin. *Flow cytometric detection of MRP in 
cells permeabilised for 10 min with 10% lysing solution G (v/v) 
(Becton Dickinson) (from [50]). §Flow cytometric detection of MRP 
in cells permeabilised for 5-10 s with ice-cold 2% formalin solution 
in acetone. In both cases, labeliing with MRPrI (1.7 fig/ml, 60 min, 
room temperature) and rabbit anti-rat FITC (Dakopatts, l:lOO, 45 
min, room temperature, dark). Data are ratios of mean fluorescence 
with MRPrl divided by mean fluorescence of isotype control or PBS 
(two separate experiments on different flow cytometers). 
EJC A 32/6-F 
and time, which is usually not available in a routine pathology 
setting. Interestingly, the same problems in variation of imrnu- 
nocytochemical analysis are encountered in other fields, and 
interlaboratory control studies are performed in order to ana- 
lyse the influence of variables (fixation, primary antibody, 
RAM and APAAP dilution, incubation times and ternpera- 
tures, counter stains, etc.) [42]. Such quality control studies 
are just beginning to be performed in the MDR field (results 
of Memphis MDR detection workshop, Beck and colleagues 
[SS]). In addition, there is a clear place for anti-Pgp antibodies 
with higher affinity for Pgp than the presently available anti- 
bodies, which would allow us to use lower concentrations of 
antibody with lower background staining (see also at flow 
cytomeny) [43]. 
Flaw cytometry 
To address the issue of cellular heterogeneity, which is likely 
to play a role in the determination of Pgp or MRP in many 
clinical tumour samples, flow cytometry seems to be parti- 
cularly suited. Firstly, the problems of Pgp flow cytometric 
assays have been mainly related to their sensitivity, quantit- 
ation, standardisation and quality control, a typical example 
of the transition from classical pathology to analytical cellular, 
quantitative pathology [l I]. Secondly, flow cytometry seems 
to be limited mainly to haematological malignancies, until 
procedures to obtain single cell intact tumour cell populations 
by disaggregation of solid tumours are more efficient. This 
discussion will only deal with Pgp and MRP detection in 
haematological malignancies, since Pgp detection by flow 
cytometry in clinical solid tumours has not been reported. 
A third consideration is that, in principle, flow cytometry 
allows Pgp or MRP measurement in certain subpopulations 
of cells (e.g. CD34+ cells) or a combination with a functional 
drug pump assay (see below). 
A vital point for flow cytometric Pgp detection is the choice 
of antibody. All available evidence strongly supports the use 
of antibodies recognising a cell surface epitope of Pgp 
(MFX16, 4E3, UICZ or others) instead of those directed 
against an intracellular epitope (C2 19, C494, JSB-1 or others) 
[35]. The former can be used to stain intact cells, which 
eliminates the need for permeabilisation of the cells, leading 
to a possible decrease in the signal-to-noise ratio [44]. More- 
over, the use of intact, viable cells allows for the combined 
assessment of Pgp and its function by dual parameter flow 
cytometry. Unfortunately, rnonoclonal antibodies against cell 
surface epitopes of MRP have not yet been described. 
One disadvantage of the use of antibodies against cell sur- 
face epitopes might be epitope masking by sialic acid residues, 
which has been reported for chronic lymphocytic leukaemia 
blast cells (451. Since we did not find any effect of neurarninid- 
ase treatment of AML samples on staining with MRK-16 
[46], it may have to do with suboptimal concentrations and 
staining conditions, used in the former study (2.5 fig/ml, 30 
min at 0%). Our present conditions are 25 p&n1 MRK-16, 
60 min at room temperature; saturation was only approached 
when 100 &ml was used [46], Thus, because of the low 
affinity of antibodies, such as MRK-16 or UIC2, in combi- 
nation with the low Pgp expression in clinical tumour samples 
and normal blood cells (we have estimated that KB8 cells 
have in the order of 20000 Pgp molecules and KB8-5 and 
82261dox4 cells in the order of 200000 using the QifikitR 
(Biocytex, Marseille, France)]) [47], a high concentration of 
isotype control antibody is applied, which is presumed to 
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produce similar background fluorescence to the test antibody 
[26]. However, this is not the case with all brands or batches 
[46]. Alternatively, the use of a high concentration of second- 
ary antibody has been advocated in order to enable the detec- 
tion of Pgp expression in bone marrow cells [48]. These 
examples again show that it is essential to perform quality 
control experiments using low level Pgp expressing cell lines, 
such as KB8 cells [3] and to use a combination with other 
techniques, such as functional assays. 
An important point is that, because the expression level of 
Pgp in clinical haematological samples is usually around the 
KB8 level, a considerable overlap between negative control 
antibody-labelled cells and test cells is obtained. Therefore, 
one has to express the data as a shift of the mean (or median) 
and not as percentage positive cells [35]. Another possibility 
is to use Kolmogorov-Smirnov statistics for comparison of 
positively stained cells with controls [35]. However, both 
methods of data representation showed excellent correlation 
[49]. Increased sensitivity of detection may be reached by 
using biotin-avidin-Texas RED instead of FITC labelling 
[49]. Irrespective of the method, one should establish the 
detection threshold of the adopted procedure with an appro- 
priate control cell. 
Since, as yet, no monoclonal antibodies against cell surface 
epitopes of MRP have been described, we have used plasma 
membrane permeabilisation methods in combination with the 
MRPrl antibody [29] to measure MRP expression in tumour 
cell lines and AML samples. Table 1 shows that this procedure 
did not give a consistent resolution of the lowest resistant cells 
within the relevant range of resistance. SW-1573 (MRP) 
transfectant cells with a resistance factor of 3-4 were easily 
detected [50]. The majority of AML samples, assessed with 
this procedure, gave a value at or below GLC4 and SW-1573 
“sensitive cells” (Broxterman and colleagues, unpublished). A 
factor which may lead to unsatisfactory sensitivity in detecting 
the lowest levels of MRP-mediated resistance is the finding 
that low levels of resistance may not be related to increased 
expression of MRP protein, but to slightly altered (increased 
glycosylated) MRP protein [5 11. For this reason, it would be 
important to measure only plasma membrane MRP in intact 
cells. For a correlation of MRP protein with MRP function 
see below. 
DRUG TRANSPORT OR FUNCTIONAL ASSAY 
A particularly suitable opportunity for specific detection of 
the MDR phenotype is probing the functional drug trans- 
porter phenotype. Such assays have the clear advantage that 
they measure the relevant property of the MDR-related pro- 
teins, i.e. their transport capacity. Moreover, the testing of 
pump inhibitors may give a lead to treatment of a patient with 
the most effective modulator. Different techniques to probe 
MDR transport function will be discussed here. 
Since we require a high sensitivity for the assays, only 
fluorescent or radiolabelled probes are discussed here. Many 
highly fluorescent dyes are transported by Pgp or MRP and 
the application of these molecules to detect the MDR-related 
drug transport in cancer cells may become a successful analyti- 
cal application of fluorescent probes in oncology. 
Flow cytometry 
By far the most widely used technique to probe Pgp function 
is the assessment of fluorescent dye or drug accumulation or 
efflux by flow cytometry. This can be done by virtue of the 
fact that many fluorescent dyes are hydrophobic compounds, 
which are efficiently taken up and transported out of the cell 
by Pgp. In the past, the accumulation of such dyes has been 
used to assess other characteristics of the cell, but it is now 
known that their active transport has to be taken into account. 
Among these dyes are rhodamine 123 (R123; mitochondrial 
dye), Hoechst 33342 (DNA binder), BCECF-AM (pH 
indicator), DiOCz(3) (membrane potential indicator), Fura- 
2-AM and Fluo-3-AM (calcium ion indicators), calcein-AM 
(viability probe and cytoplasmic marker) and the anthracy- 
clines, daunorubicin (Dnr), Dox and idarubicin (Ida) (DNA 
binders). 
When choosing an optimal probe for the assessment of I’gp 
activity, a number of factors have to be considered. Theoreti- 
cal requirements for an ideal MDR probe are summarised in 
Table 2. Essentially, these criteria refer to the probe’s sensi- 
tivity, selectivity and practicability. There are no publications 
which have compared all the possible probes in low resistant 
cell lines and in clinical samples. Therefore, the following 
considerations are by no means exhaustive in that the single 
best Pgp or MRP test has not necessarily been identified yet. 
Probes for Pgp functional assays. Although different studies 
are not comparable because of different concentrations of dyes 
or modulators, incubation times and inclusion of a dye efflux 
period in the assay, it seems to be generally accepted that 
R123, DiOC,(3) and calcein-AM are sensitive Pgp probes if 
assessed in combination with a resistance modulator such as 
SDZ PSC833 [48-501. If such a modulator for assessing the 
difference in dye accumulation with and without Pgp activity 
is not used, the assays are, in general, much more difficult. 
Differences in absolute accumulation may be caused by small 
differences in, for instance, the number of mitochondria 
(Rl23), membrane potential (DiOC,(3)), DNA content 
(Dnr), acidic cytoplasmic vesicles (Dnr) or, in general, by 
viability of the cells or small differences in experimental pro- 
cedures. Therefore, inclusion of a modulator in the assay 
greatly enhances the accuracy and reliability of the assay. 
Drugs should not be used at too high concentrations, to 
avoid possible saturation of pump capacity, especially in low 
Pgp-expressing cells. For instance, the saturation of Dnr trans- 
port as well as DNA binding begins to have affect above 2 PM 
for Pgp as well as MRP [52, 531. Alternatively, if the number 
of cells is too high, the medium concentration of a drug may 
fall too much. In such a case, the effect of a pump inhibitor 
may be estimated erroneously low. This may occur more 
Table 2. Theoretical requirements for an ideal multidrug resistance 
(MDR) probe 
1. General fluorescence properties for flow cytometry (high 
fluorescence and no or reproducible quenching) 
2. High cellular accumulation (or high distribution volume) 
3. Rapid equilibration 
4. High ratio of active to passive plasma membrane passage 
5. Rate of plasma membrane transport determines the total loss rate 
of probe from the cell 
6. pH-independent transmembrane transport 
7. Membrane potential-independent transport 
8. All properties, except MDR-related efflux, unaffected by pump 
inhibitors (among others, intracellular probe distribution and 
passive membrane transport) 
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readily when a very lipophilic drug, such as Ida, is used in a 
functional assay [54, 551. 
Modulators for Pgp functional assays. The choice of modu- 
lator is also critical. The concentration of the modulator 
should be high enough to inhibit completely the active dye 
transport by Pgp, but higher concentrations may increase the 
risk of non-specific (not Pgp related) effects on dye accumu- 
lation. A low specificity for Pgp may even be found with 
commonly used modulators such as verapamil or cyclosporin 
A at fairly low concentrations (e.g. 8 PM verapamil [46] or 
3 FM cyclosporin A [49,56], but this also depends on the dye 
or drug used with the modulator 157, 581. Based on cell 
line experiments 1501, we studied fresh AML samples and 
compared the modulation of R123 and Dnr fluorescence by 
2 PM SDZ PSC833 with modulation of radiolabelled Dnr or 
vincristine accumulation by 2 JLLM SDZ PSC833 or 8 PM 
verapamil. Based on correlation with MRK-16 staining, we 
concluded that in AML, SDZ PSC833 seems to be a specific 
modulator of the transport of all three drugs by Pgp 1461. For 
the choice of modulator, it should always be determined 
whether it influences the fluorescence yield of the probe when 
both are intracellulary present. It should be noted that we 
have seen drug pump-independent effects of PSC833 on 
RI23 fluorescence in certain cell lines, but this did not seem 
to interfere significantly with the high sensitivity of the assay 
for Pgp function as measured by flow cytometry. Importantly, 
the effect of SDZ PSC833 on R123 fluorescence is highl? 
predictive for its effects on Dnr accumulation [46]. 
~o~d~~ioF~s for pgp ~~nr~iori~l assays. It is Ckar that assays 
for an ATP-dependent plasma membrane process require 
conditions which allow the cells to be assayed while main- 
taining their metabolic and membrane integrity throughout 
the entire procedure. A minimal, but not sufficient require- 
ment is that the cells exclude Trypan blue before and after the 
assay. ATP concentrations have to be quite high for optimal 
pump activity [52]. Optimally cultured, logarithmically grow- 
ing, freshly harvested cells will usually be in a good condition 
for a functional assay. Mild trypsinisation does not seem to 
compromise drug efflux, but the conditions of attached grow- 
ing cells may decline when stored at room temperature. Since 
we and others [59] have noticed a partial decrease of drug 
efflux function upon storage of blood samples, the use of 
freshly isolated leukaemic samples is recommended for a 
functional assay. For this reason, we also prefer short-lasting 
assays, instead of long duration efflux assays. Probably, a 
R123 or DiOC, efflux assay can be applied on correctly frozen 
(in liquid nitrogen) and thawed AML or normal lymphocytes 
[ 18,20,46,49]. Cells thawed after storage in liquid nitrogen 
are usually allowed to recover in a high protein-containing 
medium (20% or more fetal calf serum). The functional assays 
are usually carried out in medium containing a high capacity 
buffer iHepes), and in the presence of 10% fetal calf serum to 
allow stable (pH) conditions and minimise drug binding to 
vials. It has to be noted that the use of (higher concentrations 
o$) fetal calf or human serum or serum albumin. profoundly 
influences the net effect of an added modulator because of 
protein binding 1601 and the putative presence of endogenous 
modulators 16 11. 
MRPjmctional assays. Although much less experience has 
been obtained with functional MRP assays, the same general 
considerations with regard to cellular conditions etc. for Pgp 
functional tests (see above) still hold. However, an important 
additional factor to be kept in mind is that the efflux of 
positively charged or neutral anticancer drugs or dyes 
(anthracyclines, vincristine, etoposide, R123) is dependent on 
the intracellular glutathione concentrations [6, 62-641. Even 
a moderate depletion of intracellular glutathione may decrease 
the transport rate of these drugs by MRP [62]. Therefore, an 
accurate measurement of the efflux of such drugs by MRP 
may also require monitoring of the intracellular glutathione 
levels during the drug transport assay. The measurement of 
cellular glutathione can, in principle, be performed by flow 
cytometry or fluorescence microscopy, but is far from being 
routinely applicable. The interested reader is referred to sev- 
eral recent research papers on this subject [65-691. If sufficient 
material is present, conventional biochemical assays for intra- 
cellular glutathione concentrations can be performed. 
Since it has been shown that fluorescent organic anions, 
such as calcein or BCECF, are substrates for MRP, in contrast 
to Pgp, and since their efflux does not change after partial 
glutathione depletion 170, 7 11, they may be used for an MRP 
functional assay. In fact, the use of calcein-AM to load cells 
with calcein provided a much more sensitive assay for MRI? 
function than, for instance, R123 efflux. Since, in combination 
with an organic anion modulator, such as probenecid, sulphin- 
pyrazone or benzbromarone 1’70, 711, the assay is specific for 
MRP, even a simple, short calcein-AM accumulation instead 
of the need for a calcein efflux measurement seems possible. 
Wowever, caution is called for because the effect of modulators 
on transport of the organic anion may not be predictive for 
their effects on (positively charged) anticancer drugs [70,7 I]. 
As to the sensitivity of the calcein-based MRP assay, we 
could detect basal efflux activity in HL60 leukaemia, SW- 
1573 and GLC, parent cells, when defined as inhibition of 60 
min calcein efflux by probenecid [71]. On the basis of MRP 
staining, these cells would all be expected to have some basal 
MRP activity [50] (see Tables 1 and 3). We could easily 
identify overexpression of MRl? activity in the SW-1573 
(MRP) transfected cells by using the calcein-AM/probenecid 
assay [71]. A Dnr/genistein assay was of similar sensitivity 
[50]. Since we cannot distinguish GLC4 cells from GLC*- 
ADR, cells (see Table 3), an even more sensitive functional 
MRP assay would be needed to analyse the small differences in 
drug efflux that might be relevant in clinical tumour samples. 
Radiolabelled drug-based assays 
The earliest experiments measuring Pgp efflux function 
made use of mdiolabelled substrates. Their use in clinical 
detection of Pgp function has remained far behind fluor- 
escence-based measurements, primarily because they are con- 
sidered to be laborious and because the handling of radioactive 
materials is supposedly not compatible with routine testing 
[72]. Although these practical drawbacks may be partly true, 
depending on the local laboratory facilities, it has to be con- 
sidered that radiolabelled accumulation assays have some 
theoretical, scientific advantages above fluorescence measure- 
ments. These assays can be performed very accurately if 
sufficient cells are available [60, 73, 741. Advantageous is 
the fact that interference by slight differences in reaction 
conditions or by the added modulator of drug transport, as 
are frequently observed with fluorescence measurements, is 
less likely. Secondly, a number of important anticancer agents 
can be studied which have unfavourable fluorescence proper- 
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Table 3. Functional multidrug resistance protein (MRP) assays using daunorubicin and calcein-AM 
Cell line 
Daunorubicin 
accumulation 
ratio 
Calcein 
accumulation 
ratio 
Calcein 
efflux ratio 
MRPrl/isotype 
ratio 
HL60 1.05* 1.06t 1.1* = 2.5s 
HL60/ADR 1.6 4.7 2.6 -15 
GLC, 1.0 1.0 1.1 1.8 
GLC,-ADR, 1.1 1.05 1.1 2.6 
GLC,-ADRpr 1.4 1.3 1.2 4.7 
GLC,-ADR,,, 2.2 2.3 2.1 21.1 
*Ratio of daunorubicin accumulation (2 PM, 60 min) with or without genistein (200 PM); data are from [50]. 
tCells are loaded for 10 min with 0.0550.5 calcein-AM with/without 1 mM probenecid or 100 PM benzbroma- 
rone. Data are ratios of calcein fluorescence with or without modulator (n=three experiments). *After loading 
with calcein-AM the cells were washed and calcein was expelled for 30 min with or without modulator present. 
Data are ratios of calcein fluorescence with/without modulator (n=three experiments). §Ratios of mean 
FITC fluorescence with MRPrl primary antibody/isotype control antibody (2% formalin/acetone fixation) 
(n = one experiment). 
ties, such as etoposide, vinca alkaloids or methotrexate. nuclear Dnr in blast cells after incubation with or without 
Thirdly, these assays give an absolute value of drug accumu- modulator, after fixation of the cells with formaldehyde, 
lation in (femto) moles per cell, which is difficult to obtain by according to Willingham and colleagues [79]. With this pro- 
flow cytometry because methods to standardise flow cyto- cedure, the nuclear Dnr remains fixed, whereas the cytoplas- 
metric procedures are still evolving [22,46, 751. Therefore, in mic Dnr is lost. Since it is the nuclear Dnr that is important 
certain cases, for instance for verification or support of for its cytotoxic action, this allows quanitification of the rel- 
important data, radiolabel-based assays should be considered. evant pool. An example of such an assay is shown in Figure 2, 
In this way, we were able to translate a certain value for where &p-negative KB3-1 cells and Pgp-positive KBS-5 cells, 
R123 efflux data in AML to a percentage increase in Dnr as well as &p-positive AML, are incubated with Dnr with and 
accumulation [46]. Also, the finding that SDZ PSC833 without SDZ PSC833 and then fixed on to cytospins. The 
increased Dnr fluorescence in AML to the same extent as effect of the modulator on nuclear Dnr fluorescence can 
radiolabelled Dnr, indicated that SDZ PSC833 had no major clearly be seen. Although the procedure is simple and requires 
effects on Dnr fluorescence properties at the conditions used. small tumour samples, a Dnr-based method may not be 
If it is decided to apply a radiolabelled drug assay, exper- 
imental variables, such as viability of cells, medium compo- 
sition, use of thawed cells etc., of course, have to be controlled, 
as in the case of fluorescence-based experiments. 
Laser scanningfEuorescence microscopy 
An alternative approach to the detection of the uptake of 
fluorescent molecules in cells is the use of a fluorescence 
microscope. Advantages compared to flow cytometry are that 
a small sample number can be studied and that the intracellu- 
lar distribution of fluorescent molecules can be visualised. If a 
laser scanning fluorescence microscope combined with com- 
puterised image processing is applied, intracellular processes 
can, in principle, be followed in time. The method is not 
suitable for high capacity screening. The number of cells that 
needs to be analysed will depend on the heterogeneity in the 
sample as to the levels of the resistance phenotypes and the 
percentage of resistant cells present. 
In order to measure Pgp or MRP protein or function, in 
principle, the same molecules can be used as for flow cytome- 
try. We have used this approach in the past to show that, in 
MDR tumour cell lines with Pgp or MRP overexpression, the 
ratio of nuclear to cytoplasmic Dox (N/C ratio) is decreased 
compared to the drug-sensitive parental cell lines [76-781. 
This was the case even in low-resistant cells [77]. Based on 
these data, we undertook an analysis of AML blast cells and 
have found that, upon incubation of these cells with Dox, the 
Dox N/C ratios were significantly lower in a group of patients 
refractory to chemotherapy compared to responding patients 
[22]. A modification of this procedure might be to measure 
Figure 2. Fluorescence microscopic image of nuclear dauno- 
rubicin fluorescence in KB3-1 cells (left), P-glycoprotein 
(Pgp)-positive acute myeloid leukaemia (AML) (middle) and 
KBS-5 cells (right) after 75 min incubation with 2 /.LM daunoru- 
bicin without (top) or with (bottom) 2 PM SDZ PSC 833. Cells 
were cytocentrifuged and fixed for 5 min with 3.7% formal- 
dehyde. 
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sensitive enough to detect the lowest (clinically relevant?) 
levels of pump activity. Refinement of analysis with this and 
other probes, nevertheless, may have potential if the goal and 
design of the experiments are carefully chosen. One such 
application might be the detection of intracellular glutathione- 
S-conjugates in intracellular vesicles in MRP research [80]. 
Pgp and MRP activity in solid turnours 
Virtually no measurements of Pgp or MRP activity in pati- 
ents’ tumours have been done. A probe proposed for in vivo 
monitoring, which has been applied to mouse tumours, is the 
use of the organotechnetium complex [99mTc] SESTAMIBI, 
which is pumped by Pgp [8 11. Experiments designed to meas- 
ure ex vivo Pgp or MRP activity in dissociated solid tumour 
cells, with techniques described above for leukaemias, are now 
in the pioneering phase [82-831. 
CONCLUSION 
Recommendations for the measurement of Pgp or MRP 
in clinical tumour samples are, in general, to apply Good 
Laboratory Practice standards: to use more than one method 
or antibody to obtain insight into the accuracy of the results of 
assays or to use controls (cell lines) which undergo as many 
steps as possible of the same analytical procedures. Specific 
protocols for each method have to be proven to work in each 
investigator’s hands. In conclusion, it is not an easy task to 
translate laboratory experiments into clinical practice, but if 
we want to learn the meaning of Pgp or any other (resistance) 
marker in clinical practice, then the assays have to be rigor- 
ously controlled. After many years of experience in the MDR 
field, we are still in this learning process. Obviously, the 
concept that intracellular drug concentrations might increase 
in Pgp-overexpressing tumour cells by co-medication with 
Pgp inhibitors (resistance modulators), leading to increased 
tumour cell kill, has not yet been proven in the clinic, 
especially not for the treatment of solid tumours. The reasons 
for this are not known, but might include the absence of Pgp 
in the tumour cells, which are important for responses, in the 
small contribution of Pgp to clinical drug resistance caused by 
partial (in vivo) inhibition of Pgp by endogenous substrates 
or the relative abundance of other resistance mechanisms 
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